Moreover, the recent favorable reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm by CMS will likely allow Tempus to aid clinicians in identifying patients at ...

Moreover, the FDA cleared Tempus’ xT CDx. This is a 648-gene tumor profiling test. The FDA also cleared its ECG-AF algorithm, which is used for cardiac risk assessment. CMS followed by approving ...

Health Monitoring: Patients can track symptoms, mood, medications, as well as connect directly with Apple Health and Google Fit to automatically sync sleep, movement, exercise, and heart rate data.

We recently published a list of 10 AI News Taking Wall Street By Storm. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against other AI news taking Wall ...